You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Wireless, implantable optofluidic systems for programmed pharmacology and optogenetics

    SBC: Neurolux, Inc.            Topic: 101

    Project Summary/Abstract Neuroscience research over the last decade has been revolutionized by many technological advancements. Pharmacology and optogenetics represent two distinct, and sometimes complementary tools used in neuroscience research to study the central and peripheral nervous systems in the context of the BRAIN initiative. Advanced interrogations of underlying neural circuits and biol ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Monochromatic 222 nm UV light: Development of a safe, cost-effective technology for the efficient reduction of bacterial and viral infection and transmission

    SBC: EDEN PARK ILLUMINATION, INC.            Topic: NIAID

    Drug resistant bacteria such as MRSA, and airborne-transmitted microbes such as influenza and TB, present significant health issues, with major healthcare and economic consequences. UV light is a well-established highly-efficient anti-microbial modality, effective both against both bacteria and viruses. However it is not possible to use UV sterilization in scenarios where people are present becaus ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Developing a peptide-based oral drug to prevent kidney stones

    SBC: Oxalo Therapeutics, Inc.            Topic: 400

    Project Summary/Abstract Kidney stones (KS) are highly prevalent, excruciating, and associated with long term complications of chronic kidney disease (CKD) and end stage renal disease (ESRD). They account for 1.3M ER visits and andgt;$10B of medical costs annually and have a striking recurrence rate of 50% in 5 years and up to 80% in 10 years, reflecting the inadequacies of current interventions. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. 4-(Aminomethyl) benzamides as novel anti-Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Ebola (EBOV) and Marburg (MARV) viruses belong to the Filoviridae family and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction after an incubation period of 4-14 days. Due to safety concerns, these viruses are designated as biosafety level 4 agents. Currently, there is no effective vaccine or therapeutic treatment for filoviral infections in humans. Africa has recen ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. An Automated Patient Chart Error Detection System for Radiation Therapy

    SBC: Infondrian LLC            Topic: 101

    Project Summary/Abstract Every year, approximately 1,200 severe mistreatments happen in radiation therapy. Radiation therapy lawsuits rank in the top third of all medical specialties with an average of $313,000 per claim settled or litigated. The current method for detecting treatment errors is by a weekly patient chart check, where each treatment record is manually reviewed on a weekly basis. Thi ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. An Ultra filtrate perfusion bio artificial pancreas for high-density islet replacement without immunosuppression

    SBC: Cell-Safe Life Sciences LLC            Topic: NIDDK

    DESCRIPTIONprovided by applicantThe Cell SafeTM is a fundamentally new approach in replacement of dysfunctional insulin producing cells in patients with diabetesby transplantation of new islets in a three dimensional scaffold embedded in a highly compatible bioengineered perfusion system that continuously supplies tissue fluidblood ultrafiltrateso that the cells ae protected from immune rejection ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. A mobile app to reduce treatment-related financial burden for cancer patients

    SBC: Vivor, Llc            Topic: NCI

    There is a fundamental knowledge gap in how to immediately reduce cancer patientstreatment related financial burdenCancer patients pay more out of pocket for their care than those with other chronic illnessesHalf of all elderly cancer patients have high treatment related out of pocket financial burdenThis financial burden has well defined harmful effects even among insured cancer patients includin ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Albumin Nanoparticles Incorporating Piceatannol (PANPs) for ALI/ARDS therapy

    SBC: Nano Biotherapeutics, Inc.            Topic: NHLBI

    Sepsis induced ALI ARDS is a devastating syndrome of acute respiratory failure in critically ill patients that accounts for among the highest admission rates in ICU and mortalityDuring STTR Phasewe at Cell Biologics Incdemonstrated that piceatannola naturally occurring anti inflammatory that selectively inhibits Syk tyrosine kinasewhen entrapped in innm albumin nanoparticlesPANPswas therapeuticall ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. A brief iPad based screening measure for HIV associated neurocognitive disorders

    SBC: Digital Artefacts LLC            Topic: 105

    Despite significance advances in anti retroviral treatments HIV associated neurocognitive disorder HAND remains prevalent and can affect a broad range of everyday activities An effective brief cognitive screen that could be implemented in busy HIV clinics where clinicians have limited time to provide care for patients with complex medical psychiatric and cognitive conditions has the poten ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Newborn Infant Vision Test

    SBC: Precision Vision, Inc.            Topic: N

    Project Summary! This STTR Phase II project continues the development of the Newborn Acuity Cardstm and the Newborn Contrast Cardstm Together these Newborn Cards form a new clinical test of visual acuity and contrast sensi tivity for use on newborn full term and preterm infants The stimuli are square wave gratings which the examiner presents to the infant in a fixation and following protocol ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government